March 23rd 2023
Zynyx will be priced comparable to other PD-1 inhibitors currently available to treat metastatic or recurrent locally advanced Merkel cell carcinoma, a rare skin cancer.
March 10th 2023
February 28th 2023
FDA Approves Lilly’s BTK Inhibitor for Rare Blood CancerJanuary 27th 2023
Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor. It has a wholesale acquisition cost of $21,000 per 30 days of therapy.